Monte Rosa Therapeutics (NASDAQ:GLUE) COO Sells $41,344.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,176 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total transaction of $41,344.00. Following the sale, the chief operating officer directly owned 62,371 shares in the company, valued at $1,185,049. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ GLUE opened at $18.31 on Friday. The firm’s 50 day moving average price is $18.65 and its 200-day moving average price is $18.48. The company has a market cap of $1.55 billion, a PE ratio of -12.37 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. On average, analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

GLUE has been the topic of several recent analyst reports. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wells Fargo & Company reduced their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Guggenheim dropped their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. boosted their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its holdings in Monte Rosa Therapeutics by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after acquiring an additional 481,844 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after acquiring an additional 257,547 shares in the last quarter. State Street Corp lifted its position in Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after acquiring an additional 1,054,406 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock valued at $18,896,000 after purchasing an additional 53,278 shares during the last quarter. Institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.